Inversago Pharma Announces New Data to be Presented at the 2023 American Thoracic Society International ConferencePosted by On




MONTREAL–(BUSINESS WIRE)–Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in a mouse model of obese asthma at the American Thoracic Society (ATS) International Conference taking place from May 19-24, 2023, in Washington, D.C. In an oral presentation, Carolyn R. Morris, PhD, Facult



Source link

Business

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.